Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ZIZ
|
|||
| Former ID |
DNCL002340
|
|||
| Drug Name |
DMUC-5754A
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 1 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 1 | [1] | ||
| Peritoneal cancer [ICD-11: 2C51.Z] | Phase 1 | [1] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ovarian carcinoma antigen CA125 (MUC16) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.